Phio Pharmaceuticals’ (PHIO) Buy Rating Reiterated at HC Wainwright

Posted by on Aug 26th, 2026

Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Phio Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $14.00.

Read Our Latest Stock Report on PHIO

Phio Pharmaceuticals Trading Up 1.7%

Shares of PHIO stock opened at $1.19 on Wednesday. The business’s fifty day simple moving average is $1.05 and its 200-day simple moving average is $1.13. Phio Pharmaceuticals has a 12-month low of $0.81 and a 12-month high of $4.19. The company has a market cap of $13.83 million, a PE ratio of -0.92 and a beta of 0.82.

Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36). On average, equities analysts forecast that Phio Pharmaceuticals will post -1.41 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Cetera Investment Advisers lifted its position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) by 26.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,500 shares of the company’s stock after buying an additional 9,000 shares during the quarter. Cetera Investment Advisers owned approximately 0.39% of Phio Pharmaceuticals worth $45,000 at the end of the most recent reporting period. Institutional investors own 57.31% of the company’s stock.

Phio Pharmaceuticals Company Profile

(Get Free Report)

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.

Featured Articles

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.